Company intelligence / Profile preview

长春海基亚生物技术

Changchun, Jilin, China

Ownership: Private
Development stage: Other

Overview

Changchun Haijiya Biotechnology is a Chinese biopharmaceutical company focused on the research, development, and commercialization of human vaccines. The company's flagship product is its freeze-dried rabies vaccine (Vero cell) for human use, which is manufactured at its facilities in Changchun. It operates within the high-tech industrial hub of Jilin Province, specializing in large-scale biological production and infectious disease prevention. The company maintains GMP-certified manufacturing lines to supply the domestic Chinese market with essential immunization products.

Therapeutic areas: Infectious Diseases
Modalities: VaccineBiologic
Industry: Biotech

Beyond the preview

Go deeper on 长春海基亚生物技术.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 长春海基亚生物技术.

Explore the full profile